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Involvement of HB-EGF and EGF receptor transactivation in The pathogenic relevance of transforming growth
TGF-–mediated fibronectin expression in mesangial cells. factor- (TGF-) to glomerular sclerosis has been estab-
Background. Gq-coupled receptors are known to transacti- lished based on a great deal of clinical and experimental
vate epidermal growth factor receptor (EGFR) via the Ca2
evidence [1, 2]. TGF- was found to cause extracellularand PKC pathways to phosphorylate extracellular signal-regu-
matrix accumulation by enhancing mesangial cell pro-lated kinase (ERK).
Methods. We studied the involvement of EGFR in trans- duction of collagen and fibronectin (FN) [3, 4]. TGF-
forming growth factor- (TGF-)–mediated fibronectin (FN) initiates responses through binding to cell-surface type-1
expression using glomerular mesangial cells. and type-2 receptors that contain serine/threonine kinase
Results. TGF- up-regulated FN mRNA accumulation in a
motifs in cytoplasmic domains [5], which implies the ini-time- and dose-dependent manner, which was completely in-
tiation of a phosphorylation cascade as the early step inhibited by phosphatidylcholine-phospholipase C (PC-PLC) in-
receptor signaling. The Smad proteins are key intermedi-hibitor and PKC inhibitors (calphostin-C and staurosporin).
The EGFR inhibitor AG1478 completely abolished TGF-– ates in the signaling process linking TGF- receptors to
mediated FN expression. ERK inactivation by PD98059, and cellular responses and are associated with synthesis of
p38MAPK inhibitor SB203580 also showed significant inhibi- extracellular matrix proteins at the transcriptional leveltory effects. Addition of neutralizing anti-heparin-binding EGF-
[6, 7]; upon binding of TGF- to its receptor, Smad2 andlike growth factor (HB-EGF) antibody, pretreatment with hep-
Smad3 undergo serine phosphorylation, and translocatearin and the metalloproteinase (MMP) inhibitor batimastat
blocked FN expression. In mesangial cells stably transfected with to the nucleus after associating with Smad4.
a chimera containing HB-EGF and alkaline phosphatase (ALP) In contrast to the TGF--specific SMAD pathway,
genes, ALP activity in incubation medium was rapidly increased TGF- also activates p21Ras protein [8] and extracellular
by TGF- (2.1-fold at 0.5 min) and reached a 3.7-fold increase signal-regulated kinase (ERK) classically associated withat two minutes, which was abolished by calphostin-C or bati-
growth factor stimulation of receptor tyrosine kinasesmastat. TGF- phosphorylated EGFR, ERK and p38MAPK
[9]. Previous studies demonstrated that phosphotidyl-in a PKC- and MMP-dependent manner. Smad2 phosphoryla-
tion by TGF- was not affected by AG1478, and HB-EGF did choline-phospholipase C (PC-PLC) and protein kinase C
not activate Smad2. FN mRNA stability was not affected by (PKC) are early intermediates in TGF--mediated ac-
TGF-. Cycloheximde did not interfere with TGF-–mediated tivation of Ras [10] and mitogen-activated protein kinase
FN expression.
(MAPK) [11, 12]. However, the signaling molecules link-Conclusions. The present study demonstrated that HB-EGF
ing the PKC signal to the Ras/MAPK pathway remain toprocessed and released via PC-PLC-PKC signaling is an inter-
be defined. Recently, G-protein-coupled receptors weremediate molecule for TGF-–mediated EGFR transactivation,
and subsequent activation of ERK and p38MAPK is involved shown to stimulate the processing and release of heparin-
in FN expression via transcriptional regulation without requir- binding epidermal-like growth factor (HB-EGF) followed
ing new protein synthesis. by transactivation of the epidermal growth factor recep-
tor (EGFR)-mediated ERK pathway [13–16]. HB-EGF
is a heparin-binding member of the EGF family and is
Key words: heparin-binding EGF-like growth factor, cell signaling,
synthesized as a transmembrane precursor that is thenglomerular mesangial cells, transcriptional regulation, glomerular scle-
rosis, extracellular matrix. proteolytically processed into the mature, soluble growth
factor. The proteolytic processing was reported to be reg-Received for publication September 19, 2001
ulated by PKC and Ca2 signaling [17]. Our current studyand in revised form April 23, 2002
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our knowledge for the first time, that TGF- stimulated medium; we constructed a pRC expression vector con-
taining the human alkaline ALP cDNA subcloned betweenthe processing and release of HB-EGF via PC-PLC-
mediated PKC activation, which in turn transactivated the human HB-EGF signal sequence and the coding re-
gion for mature human HB-EGF protein (pALP-HB-the EGFR-mediated ERK and p38MAPK cascade to
regulate of FN gene transcription. EGF) [15, 21]. Then the pAlp-HB-EGF (30 g) were
transfected into mesangial cells using Lipofectamine
Plus (Gibco BRL) and selected with G418 [15, 22, 23].
METHODS
Three stable cell lines with high ALP activity in the in-
Materials cubation medium were selected and analyzed for the
experiment. To determine the ALP activity, the incu-Heparin binding-epidermal-like growth factor (HB-
EGF), genistein, AG1478, TMB-8 and SB203580 were bation medium was heated at 70C for 10 minutes and
100 L aliquots were incubated at 37C for five minutespurchased from Calbiochem (La Jolla, CA, USA). Stau-
rosporin, calphostin-C, phorbol 12-myristate 13-acetate in assay buffer (100 L) containing diethanolamine (2
mol/L, pH 9.8), MgCl2 (2 mmol/L), homoargine (0.4 mol/L)(PMA) and heparin (porcine intestinal mucosa) were
from Sigma Chemical Company (St. Louis, MO, USA). and disodium p-nitrophenyl phosphate (12.5 mmol/L).
The sample volume was expanded to 1 mL with waterD609 was from Biomol Inc. (Plymouth Meeting, PA,
USA). Anti-FN antibody was purchased from Telios and absorbance was determined at 405 nm. The values
were normalized with cellular protein using bovine se-Pharm. Antibodies were from the following vendors:
EGFR, HB-EGF, Smad2, normal rabbit IgG (Santa Cruz rum albumin (BSA) as a standard (Pierce, Chester, UK)
and background absorbance in the medium, and areBiotechnology, Santa Cruz, CA, USA); phospho-ERK
and phospho-p38MAPK (New England BioLabs, Bev- shown relative to the time 0 control value [15].
erly, MA, USA); 4G10-HRP, phospho-Smad2 (Upstate
Measurement of ERK, p38MAPK andBiotechnology, Lake Placid, NY, USA). The metallopro-
EGFR phosphorylationteinase (MMP) inhibitor batimastat was from British
Biotech (Cowley, Oxford, UK). TGF- was purchased Tyrosine-phosphorylation of EGFR was analyzed in
cells exposed to TGF- for two minutes. Cells werefrom Immuno-Biological Laboratories.
treated with lysis buffer [22, 23]. After brief sonication,
Cell culture samples were incubated for 30 minutes at 4C, centri-
fuged for five minutes at 15,000  g and the supernatantMesangial cells were prepared from kidneys of 8-week-
old male C57BL/6 mice by the explant method as de- was incubated with anti-rabbit EGFR antibody for
16 hours at 4C. Immune complexes were removed byscribed previously [18], and cultured with Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal anti-rabbit IgG agarose beads (Sigma), transferred onto
nitrocellulose membranes by electroblotting, blottedcalf serum (FCS). Subconfluent mesangial cells (passages
4 and 5) were serum-starved for 24 hours and used for with anti-phosphotyrosine antibody and detected with
an enhanced chemiluminescence kit (ECL; Amersham,the experiments.
Tokyo, Japan) as described previously [24, 25]. Tyrosine-
Northern blotting, stable transfection of DNA and phosphorylation of ERK or p38MAPK was determined
measurement of ALP activity in cells exposed to TGF- for 8 or 30 minutes using
respective phospho-specific antibodies [22–25].Total RNA was extracted using TRIZOL Reagent
(Gibco BRL, Gaithersburg, MD, USA), fractionated on
Measurement of PKC activity1% agarose/formaldehyde gels, and transferred to nylon
membranes [19, 20]. Blots were then hybridized with Protein kinase C activity was assayed by determining
threonine phosphorylation of PKC-specific synthetic pep-random-primed 32P-labeled cDNA probes for FN and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) tide substrate (N-terminal amino acids of epidermal
growth factor receptor: Arg-Lys-Arg-Thr-Leu-Arg-Arg-as an internal control. Hybridization signals were quanti-
fied by scanning densitometry, and FN mRNA levels Leu-OH) using the commercially available assay kit (Bio-
trak; Amersham). PKC activity was normalized with thewere arbitrarily normalized relative to the GAPDH
mRNA levels. assayed protein content and shown by calculating phos-
phate transferred per minute (pmol/min). Cellular extractThere is no enzyme-linked immunosorbent assay
(ELISA) system to measure HB-EGF, and HB-EGF re- was obtained by homogenization in ice-cold buffer [50
mol/L Tris/HCl pH 5, 0.3% -mercaptoethanil, 5 mol/Lleased into incubation medium cannot be detected by
Western blotting due to its low concentrations. There- ethylenediaminetetraacetic acid (EDTA), 10 mol/L eg-
tazic acid (EGTA), 10 mol/L benzamide] containing pro-fore, we established cells stably transfected with pALP-
HB-EGF and examined the release of HB-EGF by mea- tease inhibitors [50g/mL phenylmethylsulfonyl fluoride
(PMSF), 1 g/mL leupeptin, 1 g/mL antipain].suring alkaline phosphatase (ALP) activity in incubation
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Fig. 1. Time- and dose-dependent effects of
transforming growth factor- (TGF-) on fi-
bronectin (FN) mRNA accumulation. Serum-
deprived cells were stimulated with TGF-
(5 ng/mL) for the indicated periods (A) and
at the indicated doses (B). Total RNA (15 g)
was separated on agarose formaldehyde gels
and transferred onto nylon membranes for
hybridization with 32P-labeled FN or GAPDH
cDNA probes. Densities of FN mRNA signals
were measured by densitometry and normal-
ized relative to those of GAPDH mRNA sig-
nals. The results are arbitrarily indicated as
values relative to FN mRNA levels in the un-
stimulated cells. Results shown are means 
SE of four separate experiments and represen-
tative data are shown. *P  0.05, **P  0.01
vs. the control.
Detection of FN released into medium Involvement of PC-PLC-PKC and EGFR
transactivation in TGF-–induced FNQuantification of FN secreted into medium was per-
mRNA accumulationformed as reported previously [23]. Following 12 hours
To address the role of PKC in TGF- signaling, mesan-of incubation of cells with or without TGF- (5 ng/mL),
gial cells were treated with the PKC inhibitors stauro-100 Ci/mL of [35S] methionine was added for further
sporin (40 nmol/L) or calphostin-C (100 nmol/L), known12 hours. Aliquots (100 L) of the medium were diluted
to interact with the adenosine 5-triphosphate (ATP) bind-with 900 L of RIPA buffer and followed by incubation
ing site and regulatory subunit of PKC, respectively [26, 27].with anti-FN antibody. Immune complexes were re-
These PKC inhibitors were found to completely inhibitmoved by protein A-Sepharose beads and analyzed by
TGF-–induced FN mRNA accumulation (Fig. 2). Phor-sodium dodecyl sulfate-polyacrylamide gel electrophore-
bol ester (PMA, 100 nmol/L) also markedly up-regulated
sis (SDS-PAGE).
FN mRNA levels (Fig. 2). To confirm the role of PKC,
we determined PKC activities in mesangial cells treatedStatistical analysis
with TGF-. PKC activity was assayed by determining
The results are expressed as means  SE. Statistical threonine phosphorylation of PKC-specific synthetic pep-
analysis was performed with one-way analysis of variance tide substrate (N-terminal amino acids of epidermal
(ANOVA) followed by pair-wise comparison using the growth factor receptor: Arg-Lys-Arg-Thr-Leu-Arg-Arg-
Dunnett multiple comparison test. Data were considered Leu-OH). As shown in Table 1, PKC activities were
statistically significant when P was 0.05. increased 2.6-fold at two minutes after the addition of
TGF- compared with those in the 0 time control, which
was abolished by pretreatment with staurosporin or cal-
RESULTS phostin-C.
Diacylglycerol (DAG), an endogenous activator ofTGF- stimulates FN mRNA synthesis
PKC, is generated by the hydrolysis of phospholipids.
Transforming growth factor- (5 ng/mL) significantly Recent evidence indicated that PC-PLC plays a key
stimulated FN mRNA accumulation after six hours of role in TGF-–mediated DAG production [11, 12].
incubation, reaching a maximal increase (2.4-fold) after Treatment with the specific PC-PLC inhibitor D609 (50
24 hours and thereafter maintained a similar level until g/mL) [28] resulted in half-maximal inhibition at ap-
48 hours (Fig. 1A). TGF- dose-dependently up-regu- proximately 10g/mL and complete inhibition of TGF-–
lated FN mRNA levels, producing a maximal increase mediated FN mRNA accumulation at 50 g/mL, while
at 5 ng/mL (Fig. 1B). Therefore, subsequent experiments D609 (50 g/mL) did not affect PMA-mediated FN ex-
were performed with 5 ng/mL TGF- stimulation for pression (Fig. 2). Although hydrolysis of PC-PLC yields
DAG and phosphocholine [29], it cannot generate inosi-24 hours.
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Fig. 2. Effects of protein kinase C (PKC), phosphotidylcholine-phospholipase C (PC-PLC) inhibitor, endothelial growth factor receptor (EGFR)
antagonist, and inhibitors of extracellular signal-regulated kinase (ERK) and p38MAPK on TGF-–induced FN mRNA accumulation. Serum-
deprived cells were pretreated with or without the PKC inhibitor staurosporin (40 nmol/L), calphostin-C (100 nmol/L), PC-PLC inhibitor D609
(50 g/mL), EGFR inhibitor AG1478 (1 mol/L), MEK inhibitor PD98059 (10 mol/L), or p38MAPK inhibitor SB203580 (10 mol/L) for 30
minutes, and then incubated with TGF- (5 ng/mL) or PMA (100 nmol/L) for 24 hours. Quantification of mRNA levels was performed as described
in Figure 1. Results shown are means  SE of four separate experiments and representative data are shown. *P  0.05, **P  0.01 vs. the control.
Table 1. TGF-–mediated PKC activation in mesangial cells
TGF- 5 ng/mL TGF- staurosporin TGF-calphostin
Incubation time minutes 0 2 5 10 2
PKC activity 0.890.02 2.30.05a 0.910.03 0.890.02 0.880.03 0.900.03
Abbreviations are in the Appendix. Mesangial cells were incubated with serum-free medium for 12 hours and pretreated with or without the PKC inhibitors,
staurosporin (40 nmol/L), calphostin-C (100 nmol/L), for 30 min, and then incubated with TGF- (5 ng/mL) for the indicated incubation time. PKC activity in cellular
extract was assayed by determining threonine phosphorylation of PKC-specific synthetic peptide substrate. PKC activity was normalized with the assayed protein
content and shown by calculating phosphate transferred per minute (pmol/min). Data are mean  SE (N 	 8, each).
a P  0.001 vs. 0 time control
tol 3-phosphate (IP3). As the absence of IP3 does not mesangial cells [30], whereas no intracellular Ca2 mobi-
lization was observed in TGF-–stimulated cells. Pre-result in release of intracellular Ca2, we next determined
intracellular Ca2 levels to confirm that PKC activation treatment with intracellular Ca2 chelators BAPTA-AM
(50 mol/L) and TMB8 (100 mol/L) did not affectdoes not result from hydrolysis of phosphatidylinositol-
PLC. Intracellular Ca2 level measured using fura 2-AM TGF-–mediated FN expression (data not shown), al-
though these concentrations of Ca2 chelators effectivelywas elevated approximately one minute after addition
of angiotensin II, as we have recently reported in mouse inhibited angiotensin II-mediated Ca2 mobilization in
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mouse mesangial cells [30]. Taken together, these find- ment with batimastat, indicating that PKC is located
ings suggested the involvement of PC-PLC rather than upstream of proHB-EGF processing in the TGF- sig-
phosphatidylinositol-PLC in activation of the PKC naling pathway (Fig. 3).
pathway. To further define the processing of HB-EGF by
As it was reported that the processing of HB-EGF was TGF- signaling, we established mesangial cells stably
stimulated by angiotensin II- or endothelin-1-mediated transfected with an expression vector containing ALP
PKC signaling and that the released HB-EGF transacti- cDNA between the HB-EGF signal sequence and HB-
vated EGFR [13–15], we examined whether this pathway EGF cDNA (Fig. 4A). The processing and release of
was activated downstream of TGF- signaling. Interest- HB-EGF were evaluated by measuring ALP activities
ingly, the EGFR inhibitor AG1478 completely blocked in the incubation medium. ALP activity was rapidly in-
TGF-–mediated FN mRNA expression (Fig. 2). The creased after addition of TGF- (2.1-fold at 0.5 min) and
specificity of AG1478 as an inhibitor of EGFR phosphor- reached a 3.7-fold increase at two minutes. Pretreatment
ylation was well established in our previous studies of with calphostin-C or batimastat completely abolished
dominant negative mutants of EGFR [22, 23]. the TGF--mediated increase in ALP activity, whereas
As EGFR-mediated signals were reported to activate BAPTA-AM and AG1478 had no effect (Fig. 4B). Simi-
ERK and p38MAPK in vascular smooth muscle cells [14] lar results were obtained in three different stable clones,
and squamous carcinoma cell lines [31], we next examined indicating that TGF- rapidly induces the proteolytic
whether these MAPKs are involved in induction of FN processing of pro-HB-EGF via MMP in a PKC-depen-
expression by TGF-. ERK inactivation by the MEK in- dent manner to stimulate the maturation and release of
hibitor PD98059 and p38MAPK inhibitor SB203580 sig- HB-EGF.
nificantly but not completely inhibited TGF-–mediated In mesangial cells stably transfected with the vector
FN mRNA accumulation (Fig. 2). Complete inhibition of containing ALP cDNA (pALP) without the HB-EGF
FN mRNA expression was observed by combined pre- cDNA component, ALP activity (similar to that of
treatment with PD98059 and SB203580 (Fig. 2), suggest- pALP-HB-EGF-transfected cells) was detected in the in-
ing that ERK and p38MAPK activated downstream of cubation medium, while this ALP activity did not change
EGFR differentially regulated FN expression by TGF-. after TGF- exposure. The increase in FN mRNA level
by TGF- did not differ from that in wild-type cells (dataHB-EGF is processed and released by TGF-
not shown). These findings indicated that the presencesignaling to up-regulate FN expression
of TGF-–induced ALP does not affect the respon-
As the involvement of EGFR in TGF- signaling was siveness of cells to TGF-.
demonstrated in Figure 2, we examined whether HB-
EGF is actually released via proteolytic processing by TGF- trans-phosphorylates EGFR to activate ERK
MMP after addition of TGF- to regulate FN expression.
To test whether TGF- actually tyrosine-phosphory-Figure 3 shows that addition of neutralizing anti-HB-
lates EGFR and activates ERK and p38MAPK, tyrosine-EGF antibody, heparin (100 g/mL) (which competes
phosphorylation of EGFR was maximally activated twowith cell surface-associated heparin sulfate proteogly-
minutes after addition of TGF-. The addition of cal-cans as coreceptors for HB-EGF binding to EGFR) [32]
phostin-C, batimastat, heparin or AG1478 completelyand the MMP inhibitor batimastat (10 mol/L) com-
abolished this effect (Fig. 5A). ERK and p38MAPK acti-pletely inhibited TGF-–mediated FN mRNA accumu-
vation was examined using anti-phospho ERK andlation. Batimastat has a collagen-mimicking hydroxa-
p38MAPK antibodies. ERK and p38MAPK activationmate structure, which facilitates chelation of zinc ions in
were maximally activated 10 minutes after addition ofthe active site of membrane-bound zinc-endopeptidase
TGF- (data not shown). In accordance with the resultsMMPs, including the interstitial collagenases, stromely-
of EGFR phosphorylation, both ERK and p38MAPKsins 1-3, matrilysin, 92-kD gelatinase B (MMP-9), and
activation by TGF- were abolished by pretreatmentthe 72-kD gelatinase A (MMP-2) [33]. HB-EGF also
with calphostin-C, batimastat or AG1478 (Fig. 5B).stimulated FN expression, with a significant increase at
We also examined whether EGFR signaling influencessix hours after the addition of HB-EGF (1.8  0.2-fold
TGF-–mediated Smad2 phosphorylation. As shown inincrease relative to the control). The peak expression of
Figure 5C, levels of Smad2 phosphorylation were sig-FN mRNA was observed at approximately 24 hours
nificantly up-regulated by TGF- (1.9  0.1-fold vs. con-(2.6 0.4-fold increase; Fig. 3), similar to the time course
trol, N 	 5), whereas inhibition of the EGFR functionobserved after addition of TGF- (Fig. 1A), suggesting
by AG1478 did not affect this Smad2 activation. HB-EGFthat the proteolytic processing of HB-EGF is unlikely
(20 ng/mL), which was shown to up-regulate FN expres-to be involved in the slow induction of FN mRNA ex-
sion in Figure 3, also did not change the Smad2 phos-pression by TGF-. This induction was blocked by hepa-
rin. FN induction by PMA was abolished by pretreat- phorylation level.
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Fig. 3. Effects of inhibition of heparin binding–epidermal-like growth factor (HB-EGF) processing and release on TGF-–induced FN mRNA
accumulation. Serum-deprived cells were pretreated for 30 min with neutralizing anti-HB-EGF antibody (100), heparin (100 g/mL) or the
metalloproteinase inhibitor batimastat (10 mol/L), and then stimulated with TGF- (5 ng/mL), HB-EGF (20 ng/mL) or PMA (100 nmol/L) for
24 hours. Quantification of mRNA levels was performed as described in Figure 1. Results shown are means  SE of four separate experiments
and representative data are shown. *P  0.01 vs. the control.
TGF-–induced FN mRNA expression results in an were stimulated with TGF-, the half-life was not sig-
nificantly changed (14.7  0.2 h) compared with that inincrease in FN protein release
controls. Pretreatment with cycloheximide, which inhib-To examine whether FN mRNA accumulation re-
its new protein synthesis, did not affect TGF-–mediatedsulted in induction of FN at the protein level, FN protein
FN mRNA accumulation (Fig. 6C).secreted into the medium was analyzed by immunopre-
cipitation using anti-FN antibody as described previously
[23]. The level of immunoprecipitated FN secreted into DISCUSSION
medium was increased by 1.8-fold over the control by Previous studies suggested that PC-PLC and PKC are
TGF-. Pretreatment with calphostin-C, batimastat, early intermediates in TGF-–mediated activation of
AG1478 or neutralizing anti-HB-EGF antibody com- Ras [10] and MAPK [11, 12], whereas the signaling mole-
pletely abolished TGF--induced FN release (Fig. 6A). cules linking the PKC signal to the Ras/MAPK pathway
remained to be defined. The major new findings of the
TGF- stimulates FN mRNA accumulation without present study are that (1) TGF- stimulates the processing
affecting FN mRNA stability or requiring new and release of HB-EGF via activation of MMP; (2) PC-
protein synthesis PLC-mediated PKC signaling is an upstream molecule
Next, the effects of TGF- on FN mRNA stability to activate MMP; (3) HB-EGF released into incubation
were tested by inhibiting gene transcription with actino- medium binds EGFR followed by activation of ERK
mycin D. In unstimulated control cells, the half-life of and p38MAPK to up-regulate FN gene expression; and
(4) TGF- induces FN expression without affecting itsFN mRNA was 14.2  0.2 hours (Fig. 6B). When cells
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Fig. 4. Construction of pALP-HB-EGF and
metalloproteinase-dependent release of proHB-
EGF. (A) A pRC expression vector containing
ALP cDNA between HB-EGF signal sequence
and HB-EGF cDNA (pALP-HB-EGF) was
constructed. (B) Cells stably transfected with
pALP-HB-EGF were stimulated for 2 min
with TGF- (5 ng/mL) with or without cal-
phostin-C (100 nmol/L), heparin (100g/mL),
batimastat (10 mol/L), BAPTA-AM (10
mol/L) or AG1478 (1 mol/L). ALP activity
in the incubation medium was determined as
described in the Methods section. The ALP
activities (N 	 4 in each experiment) are
shown relative to the values of 0 time control
arbitrarily given a value of 1. Results shown
are means  SE of four separate experiments
and representative data are shown. *P  0.01
vs. the control.
mRNA stability, possibly by regulation of FN gene tran- induction of FN gene expression in mesangial cells. The
MMPs, which include the interstitial collagenases, stro-scription. Thus, the present study confirms the role of
the PC-PLC/PKC pathway in TGF- signaling in the mes- melysins 1-3, matrilysin, 92-kD gelatinase B (MMP-9),
and the 72-kD gelatinase A (MMP-2), constitute a familyangial cells, and provides the first evidence, to our knowl-
edge, that HB-EGF is a major intermediate molecule to of matrix-degrading enzymes with distinctive extracellu-
lar matrix substrate specificities [33]. MMP-2 and MMP-9transmit the TGF- signal in EGFR transactivation.
The present findings also demonstrated that the pro- share similar substrate specificity, encompassing type IV
and V collagen, FN and laminin [34]. MMP-2 acts notcessing of HB-EGF by TGF- was induced rapidly (0.5
min) before maximal activation of EGFR (2 min), and only as a matrix-degrading enzyme, but also directly stim-
ulates growth of glomerular mesangial cells, and proteo-that the processing and release of HB-EGF were due to
MMP activated in a PKC-dependent manner. HB-EGF lytically-derived fibronectin cleavage fragments were
shown to be responsible for the growth-promoting andis a heparin-binding member of the EGF family and is
synthesized as a transmembrane precursor that is then pro- prosclerotic actions of this molecule [35]. The present
study extends these previous reports suggesting the in-teolytically processed into the mature, soluble growth
factor. The proteolytic processing was reported to be volvement of MMPs in the pathophysiology of glomeru-
losclerosis and adds new evidence that the glomerularregulated by PKC [14], consistent with the present find-
ings. Thus, it is likely that TGF-–mediated HB-EGF MMPs also are involved in TGF-–mediated FN synthe-
sis via processing and release of HB-EGF.release followed by EGFR transactivation is a key in
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Fig. 5. Effects of TGF- on tyrosine-phosphorylation of EGFR, ERK
and p38MAPK. Cells pretreated with inhibitors as described in Figure
3 were stimulated with TGF- (5 ng/mL) for 2 min (EGFR and Smad),
Fig. 6. Release of FN protein and effects of TGF- on FN mRNA10 min (ERK and p38MAPK) or 20 min (JNK activation). (A) Cellular
stability. (A) Cells were pretreated with inhibitors or neutralizing anti-extracts were immunoprecipitated with anti-EGFR antibody and then
HB-EGF antibody as described in Figures 3 and 4, and then exposedblotted with anti-phosphotyrosine (
PY) antibody. (B) Cellular extracts
to TGF- (5 ng/mL) for 24 hours. Cells were subsequently incubatedwere blotted with anti-phospho ERK and p38MAPK antibodies. The
with [35S]-methionine for a further 12 hours. Culture supernatants weresame filters were reprobed with anti-EGF, anti-ERK or anti-p38MAPK
used for FN immunoprecipitation as described in the Methods section.antibody. (C ) Cellular extracts were blotted with anti-phospho Smad2
Signals of 220 kD representing FN were quantified by densitometryantibody. The same filters were reprobed with anti-Smad2 antibody.
and the value in the control was arbitrarily expressed as 1 unit. Values
represent means  SE of four separate experiments. *P  0.01 vs.
controls (unstimulated cells). (B) Cells exposed to TGF- (5 ng/mL)
for 24 hours were treated with actinomycin D (5 g/mL), and then the
The present observations add to the growing body of time-dependent changes in FN mRNA level were analyzed by Northern
information indicating that TGF- signaling involves a blotting as described in Figure 1. The same experiments were repeated
four times and representative data are shown. (C ) Cells were pretreateddiverse group of cellular elements in addition to the
with cycloheximide (5 g/mL) for 4 hours and then incubated with
Smad family of proteins. TGF-–stimulated activation of TGF- (5 ng/mL) for 24 hours. Data shown are representative of those
ERK, p38MAPK and c-Jun NH2-terminal kinase (JNK) from four separate experiments. *P  0.01 vs. the control.
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have been demonstrated previously in different cell types. by TGF- are not involved in FN gene regulation. The
effect of TGF- on FN mRNA stability and the involve-Kucich et al reported that FN gene expression by TGF-
was regulated by p38MAPK but not ERK in diploid lung ment of new protein synthesis were markedly different
between mesangial cells (this study) and cardiac fibro-fibroblasts; however, they also showed that PC-PLC and
PKC signaling operated upstream of p38MAPK [12]. blasts [23]. As shown in Figure 6 panels B and C, TGF-
had no effect on FN mRNA stability or new proteinHocevar et al reported a major role of a JNK-dependent
mechanism in TGF-–mediated FN expression in a fi- synthesis. In contrast, FN mRNA stability in cardiac
fibroblasts was increased by TGF-, which was depen-brosarcoma cell line [36]. In the present study using
mesangial cells, although TGF-–mediated JNK activa- dent on cycloheximide-sensitive new protein synthesis
[23]. Thus, TGF-–induced new protein synthesis playstion was not detected by anti-phopsho JNK antibody
(data not shown), we demonstrated, to our knowledge a key role in stabilizing FN mRNA, and the cell type-
specific expression or regulation of proteins associatedfor the first time, that both ERK and p38MAPK acti-
vated downstream of EGFR were closely involved in with FN mRNA stability may be involved in the discrep-
ancies in results between mesangial cells and cardiacTGF-–mediated FN expression. Recent studies have
indicated that EGFR-mediated signals mainly activate fibroblasts.
In summary, the present study confirms that TGF-–ERK and p38MAPK, but not JNK, in vascular smooth
muscle cells [14] or a squamous carcinoma cell lines mediated PC-PLC and PKC signaling are involved in
ERK activation in mesangial cells, and demonstrates[29], consistent with our present observations. Given the
implication of Src family tyrosine kinase in p38MAPK for the first time to our knowledge that HB-EGF, the
processing and release of which are activated in a MMP-activation by Gq [37] or association of c-Src to EGFR
[38], c-Src could be a possible link connecting the trans- dependent manner, is an intermediate molecule in the
transmission of the TGF- signal to ERK/p38MAPK-activated EGFR to p38MAPK. As the roles of PC-PLC
and PKC signaling activated downstream of TGF-were mediated FN expression. Therapeutic intervention to in-
hibit glomerulosclerosis should aim toward attenuationconfirmed in diploid lung fibroblasts [12], the lung carci-
noma cell line A549 [11], and mesangial cells (in this of HB-EGF processing and blockade of EGFR function.
study), different cell types and responses may utilize
different signaling pathways downstream of the PC-PLC/ ACKNOWLEDGMENTS
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APPENDIXplays an important role in extracellular matrix accumula-
Abbreviations used in this study are: ALP, alkaline phosphatase;tion. A direct role of TGF- in glomerulosclerosis was
ATP, adenosine 5-triphosphate; BSA, bovine serum albumin; DAG,supported by the observation that FN, collagen types I diacylglycerol; DMEM, Dulbecco’s modified Eagle’s medium; EGFR,
and III expression as well as secretion of new collagen epidermal growth factor receptor; ERK, extracellular signal-regulated
kinase; FCS, fetal calf serum; FN, fibronectin; GAPDH, glyceralde-are directly stimulated by TGF- in mesangial cells [2–4].
hyde-3-phosphate dehydrogenase; HB-EGF, heparin binding-epider-Our previous report using cardiac fibroblasts found that mal-like growth factor; MAPK, mitogen-activated protein kinase;
induction of FN gene transcription by angiotensin II is MEK, ERK kinase, MMP, matrix metalloproteinase; MMP-2, 72-kD
gelatinase A; MMP-9, 92-kD gelatinase B; PC-PLC, phosphotidylcho-controlled by binding of c-fos/c-jun complex to the AP-1
line-phospholipase C; PKC, protein kinase C; PLC, phospholipase C;sequence, in which the formation of the c-fos/c-jun com-
PMA, phorbol 12-myristate 13-acetate; TGF-, transforming growth
plex was completely regulated by ERK signaling [23]. factor-.
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